Hours: 09.00 am - 05.00 pm
Email:
[email protected]Phone:
(813) 304-1777
- Phase: 2
- Study Type: Randomized Double blind placebo controlled.
- Insurance: no
- Duration: 1 year
- Benefits: $100 per visit
- From 18 to 85 years of age
- Diagnosis of SCLE or DLE documented in medical history.
- Historical skin biopsy within 10 years prior to Screening visit and confirmation of current diagnosis by skin photography at Screening visit.
Lupus Nephrtis, Epilepsy, significant cardiovascular diseases, HIV, TB
- Phase: 3
- Study Type: Double Blind Placebo
- Duration: 1 year
- Insurance: no
- Benefits: $100
- Male and female subjects aged 18 – 75 years.
- Established diagnosis of T2 Diabetes Mellitus for at least 6 months prior to Screening AND an A1C ≥ 7.5% but ≤ 11.0% at Screening.
- On a stable dose of a oral glucose-lowering agents for a period of 3 months prior to Screening.
Lupus Nephrtis, Epilepsy, significant cardiovascular diseases, HIV, TB
- Phase: 2
- Study Type: Randomized Double Blind Placebo
- Duration: 12 weeks
- Insurance: no
- Benefits: $100 per visit
- 18 to 55 years of age inclusive at the time of signing the informed consent at Visit 1
- Documented asthma diagnosis ≥ 12 months prior to Visit 1
- Able to perform acceptable lung function testing.
Mild Asthma ( should be Moderate to Severe)
- Phase: I/ II
- Study Type: open label
- Duration: 8 visits
- Insurance: no
- Benefits: $100 per visit
- Males and females who are at least 75 years of age at time of enrollment
- Good general health
- Available for the duration of the study
- Peripheral veins suitable for blood draw
No steroids, younger than
Within a small group of first-time participants, researchers test an experimental study drug or treatment.
Then, in order to determine its effectiveness and more precisely evaluate the experimental drug or treatment, it is administered to a larger group of people.
The experimental drug or treatment is given to large groups of people, confirm its efficacy and keep track of side effects.
For additional information, post-marketing studies, which are conducted after the FDA approves a treatment for use, are discussed.
- Start Date: -
- Phase:Â Phase 2
- Study Type:Â Interventional
- Duration:Â 3 Visits
- Insurance:Â No insurance is needed
- Benefits:Â Compensation up to $450 for time and travel
- From 18 to 65 years of age
- Migraine attacks, on average, lasting for 4 to 72 hours if untreated
- Migraine headaches frequency of 2 to 8 attacks of moderate or severe pain intensity per month
- Has at least 1-year history of migraine
- Diagnosis of headache condition other than migraine
- History of cardiovascular disease
- Current use of opioids or cannabis
- Have a current diagnosis of significant psychiatric illness
- Start Date: -
- Phase:Â Phase 2
- Study Type:Â Interventional
- Duration:Â 7 Visits
- Insurance:Â No insurance is needed
- Benefits:Â Compensation up to $1,500 for time and travel
- Participant ≥ 18 years of age
- Confirmed SARS-CoV-2 infection as determined by RT-PCR
- Initial onset of signs/symptoms attributable to COVID-19 within 5 days
- Has at least 1 medical condition
- History of hospitalization
- Known medical history of active liver disease
- Known HIV infection
- Prior to the current disease episode, any confirmed SARS-CoV-2 infection
- Start Date: -
- Phase:Â Phase 2
- Study Type:Â Interventional
- Insurance:Â No insurance is needed
- Benefits:Â Compensation up to $1,500 for time and travel
- From 50 to 90 years of age
- Have a clinical diagnosis of mild-to-moderate Alzheimer’s disease
- Have a reliable caregiver
- Able to swallow oral medication
- Have a current diagnosis of significant psychiatric illness
- Untreated clinical depression
- Have a history of cancer
- Clear evidence for other causes of neurodegeneration or dementia
- Significant ongoing psychiatric or substance abuse problems
- Start Date: -
- Phase:Â Phase 2
- Study Type:Â Interventional
- Insurance:Â No insurance is needed
- Benefits:Â Compensation up to $500 for time and travel
- From 18 to 85 years of age
- Diagnosis of Acute RSV infection
- Tested Positive for RSV infection
- Initial onset of signs/symptoms attributed to RSV within 5 days
- Presence of clinically significant heart arrhythmias
- Known hepatitis B or C infection
- Confirmed SARS-CoV-2 Infection
- Women who are pregnant or breastfeeding
- Start Date: -
- Phase:Â Phase 2
- Study Type:Â Interventional
- Insurance:Â No insurance is needed
- Benefits:Â Compensation up to $2,000 for time and travel
- From 18 to 75 years of age
- History confirmed by evidence from medical information
- Must have had no further head trauma in the last 6 months
- Must have TBI
- Progressive dementia
- Penetrating head trauma
- Significant symptoms of a depressive disorder
- Significant ongoing psychiatric or substance abuse problems
- Clinically significant or unstable systemic disease
- Start Date: -
- Phase:Â Phase 1
- Study Type:Â Interventional
- Insurance:Â No insurance is needed
- Benefits:Â Compensation up to $2,000 for time and travel
- From 55 to 85 years of age
- Must have a reliable informant or caregiver
- Participant weight at least 41 Kg (90 lbs) and not more than 113 Kg (250 lbs)
- Meet all criteria for MCI due to AD or mild Alzheimer's Disease
- Patients who received any investigational biological drug within less than 1 year
- Has any contraindications for MRI
- Current important illness or unstable clinically
- Any suicide attempt
